Navigation Links
Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
Date:11/6/2008

SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced top-line results from its Phase 1 clinical trial of an oral formulation of picoplatin in patients with solid tumors showing that picoplatin achieves linear and dose-dependent plasma exposure when given by the oral route. The results demonstrated that exposure to orally administered picoplatin was linear at doses below 200 mg, and that maximum exposure to orally administered picoplatin was achieved at doses of 200 mg or greater indicating sufficient bioavailability to support further clinical studies.

"Achieving sufficient bioavailability with oral picoplatin is extremely encouraging and supports further clinical development of an oral formulation of the drug, as it may provide a more convenient, flexible dosing routine for patients who would benefit from picoplatin," said Robert De Jager, M.D., chief medical officer of Poniard. "Orally administered picoplatin may be desirable for cancer patients receiving radiation therapy and in combination with other oral therapies."

Phase 1 Study Design and Results

Poniard's randomized, open-label, dose-ranging Phase 1 study was conducted at clinical sites in the United States. The trial compared the bioavailability, pharmacokinetics, pharmacodynamics and safety of picoplatin administered orally with picoplatin administered intravenously in patients with advanced solid tumor malignancies. Bioavailability refers to the fraction of an administered dose of an unchanged drug that reaches systemic circulation. In the first part of this two-part trial, patients with advanced solid tumor malignancies were randomized to
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... May 18, 2011 The Consumer Healthcare Products ... acetaminophen medicines for children, applauds the U.S. Food ... and caregivers give their children the right amount ... Committee and Pediatric Advisory Committee recommended enhancing the ...
... Kinetics, Inc. (NKI) ( www.neuro-kinetics.com ), manufacturers of ... neuro-otologic, vestibular and neurological testing, said today that ... control and analysis software. Clinical specialists ... conduct vestibular, oculomotor and optokinetic tests to detect ...
Cached Medicine Technology:OTC Industry Supports FDA Advisory Committee Recommendations on New Dosing Instructions 2OTC Industry Supports FDA Advisory Committee Recommendations on New Dosing Instructions 3Neuro Kinetics Releases Updated Version of Neuro-Otologic Control and Analysis Software 2
(Date:7/10/2014)... The benefits of medical imaging far outweigh the risks ... Way, with The Right Radiation Dose. However, overuse and ... Clinic is leading a collaborative effort to ensure a ... online in the Journal of Patient Safety , ... Commission, the Intersociety Accreditation Commission, and the Centers for ...
(Date:7/10/2014)... (July 10, 2014) A research review identifying the ... important first step in the process of developing evidence-based ... a new report published by Neurosurgery ... Neurological Surgeons . The journal is published by ... Wolters Kluwer Health . , Based on ...
(Date:7/10/2014)... localized prostate cancer were more likely to be ... effective treatments and survived for shorter times than ... UCLA study has found. , The negative outcomes ... as bias against the mentally ill, depression,s impact ... of investment in his general health and disinterest ...
(Date:7/10/2014)... new drug could prove useful in treating small cell lung ... Scientists from the Cancer Research UK Manchester Institute, based at ... Research Centre, teamed up with experts at AstraZeneca, as part ... known as AZD3965 - on small cell lung cancer ... Cancer Research , also helps identify which patients are most ...
(Date:7/9/2014)... 10, 2014 -- The World Health Organization recommends that ... moderate to vigorous physical activity (MVPA) each day. ... MVPA during school hours. Therefore, it stands to ... increase MVPA. In a new study scheduled for ... confirmed that time spent outdoors after school was positively ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Go play outside! Outdoor time promotes physical activity in youth 2
... is,a leader in serving people who are visually impaired -- ... People who are legally blind can function and lead effectively ... The news that Lt. Gov. Paterson will become Governor ... people with vision loss can,achieve great heights., As I ...
... the finding shouldn,t keep physicians from using Avastin, researchers say ... cancer drug Avastin can cause kidney damage by doing what ... study shows. , Avastin, whose generic name is bevacizumab, is ... attack cancers by cutting off their blood supply. It does ...
... 12 As previously,disclosed in its Form 8-K filed ... NHWK ) announced that Ernest G. Ludy has resigned,from ... of Directors for,personal reasons. As a result of such ... with Nasdaq Marketplace Rule,4350(d)(2) -- which requires the company,s ...
... Omega T, an Omega 3 and Turmeric ... ... makers,of Conquer HA(TM), introduce the latest addition to their family of joint,relief ... T,is powerful natural anti-inflammatory formula containing Omega 3 and,Turmeric for double strength ...
... 2008) The American Society of Nephrology (ASN), in ... American Society of Pediatric Nephrology (ASPN), will celebrate the ... and patient advocates from across the nation will hold ... raise awareness of chronic kidney disease (CKD) as a ...
... observed that cancer cells perform energy metabolism in a way ... later, this observation was exploited by clinicians to better visualize ... not been known exactly how tumor cells perform this alternate ... essential for tumor growth. , Now, two papers appearing in ...
Cached Medicine News:Health News:Doctors See How Cancer Drug Can Damage Kidneys 2Health News:Doctors See How Cancer Drug Can Damage Kidneys 3Health News:Previously Disclosed Changes in Board Composition of NightHawk Radiology Holdings, Inc. Prompt Notice of Noncompliance from the Nasdaq Global Market 2Health News:The Makers of Conquer HA(TM) Launch All-Natural Double Strength Anti- Inflammatory Formula 2Health News:ASN members visit Capitol Hill to promote World Kidney Day and CKD awareness 2Health News:Study helps explain fundamental process of tumor growth 2Health News:Study helps explain fundamental process of tumor growth 3
The base of the staple is round and threaded to enable screwing onto the stapler. The base also has spikes. The legs of the staple are contoured to prevent the staple from backing out....
The staple fixation system provides a simple means of attaching tissue to bone....
... ORTHOSET Radiopaque Bone Cement ... system: a sterile,ampule containing bone ... pack, and a sterile polyethylene ... a peelable pouch. The interiors ...
... Cement consists of a two ... bone cement liquid within a ... polyethylene bag,containing bone cement powder ... interiors of the blister pack,and ...
Medicine Products: